Diversity and Inclusion (D&I) in clinical trials remains a key challenge faced by the healthcare industry today. While many life sciences companies are just beginning down the path of enrolling a more diverse population in their clinical trials, several organizations have already made substantial inroads into ensuring participation in clinical trials better reflects the intended therapy area’s real-world population.
Experts discuss key considerations for assessing and restructuring clinical trial designs and processes to achieve better representation of target populations, including:
Complexity demands a trusted guide with the unique expertise and cross-sector versatility to deliver unwavering success. We work with organizations across regulated commercial and public sectors to catalyze transformation and pioneer new directions for the future.